Nurix Therapeutics, Inc. (NRIX) Presents at UBS Global Biopharma Conference 2026 TranscriptSeeking Alpha • Tuesday
Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and ExpositionGlobeNewsWire • 11/05/26
Nurix, Sanofi Diverge — And One Breaks Out — On A Shocking Eczema DevelopmentInvestors Business Daily • 11/04/26
Nurix Therapeutics Announces Sanofi's Decision to Discontinue Development of STAT6 Degrader SAR448272GlobeNewsWire • 11/03/26
Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement PathwaysSeeking Alpha • 10/14/26
Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass EstimatesZacks Investment Research • 10/12/26
Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 10/12/26
Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic LeukemiaGlobeNewsWire • 10/07/26
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead SciencesGlobeNewsWire • 10/05/26
Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with PfizerGlobeNewsWire • 09/29/26
Nurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference TranscriptSeeking Alpha • 09/17/26
Nurix Therapeutics, Inc. (NRIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/16/26
Nurix Therapeutics, Inc. (NRIX) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeeking Alpha • 09/10/26
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources OfficerGlobeNewsWire • 08/20/26
Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 DegraderGlobeNewsWire • 08/04/26
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaGlobeNewsWire • 08/04/26
Roche H1 Sales Decline on Currency Headwinds, Key Drugs Keep MomentumZacks Investment Research • 07/23/26
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and NeurologyGlobeNewsWire • 07/21/26